Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Amadini C, Rizzello F, et al. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 2002;16(Suppl.):13–19.
   PubMedGoogle Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult Ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.
   PubMed Web of Science ®Google Scholar
• Hibi T, Ishibashi T, Ikenoue Y, et al. Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey. Inflamm Intest Dis. 2020;5(1):27–35.
   PubMedGoogle Scholar
• Dibley L, Bager P, Czuber-Dochan W, et al. Identification of research priorities for inflammatory bowel disease nursing in Europe: a nurses-European crohn’s and colitis organisation delphi survey. J Crohns Colitis. 2017;11(3):353–359.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Panés J, Louis E, et al. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol. 2012;12(1):108.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Assche GV, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016;48(6):601–607.
   PubMedGoogle Scholar
• Frei P, Biedermann L, Manser CN, et al. Topical therapies in inflammatory bowel disease. Digestion. 2012;86(Suppl 1):36–44.
   PubMedGoogle Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of Ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769‒784.
   Web of Science ®Google Scholar
• Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748–764.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–353.
   PubMed Web of Science ®Google Scholar
• O’Donnell S, O’Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177‒186.
   PubMedGoogle Scholar
• Brunner M, Vogelsang H, Greinwald R, et al. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2005;22(5):463–470.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015;148(4):740–750.
   Google Scholar
• Naganuma M, Aoyama N, Tada T, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 2018;53(4):494–506.
   Google Scholar
• Buono AD, Roda G, Argollo M, et al. Treat to target or ‘treat to clear’ in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol. 2020;18:1–11.
   Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–1255.
   PubMed Web of Science ®Google Scholar
• Bosworth BP, Sandborn WJ, Rubin DT, et al. Baseline oral 5-ASA use and efficacy and safety of budesonide foam in patients with ulcerative proctitis and ulcerative proctosigmoiditis: analysis of 2 phase 3 studies. Inflamm Bowel Dis. 2016;22(8):1881‒1886.
   PubMed Web of Science ®Google Scholar
• Pokrotnieks J, Sitkin S. A proposed treatment algorithm for mild to moderate ulcerative colitis—with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018;53(6):799‒800.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Weisshof R, Comprehensive A. Review of topical therapies for distal Ulcerative colitis. Gastroenterol Hepatol. 2020;16:21‒27.
   Google Scholar
• Seibold F, Fournier N, Beglinger C, et al. Topical therapy is underused in patients with ulcerative colitis. J Crohns Colitis. 2014;8(1):56‒63.
   Web of Science ®Google Scholar
• Hammond A, Andus T, Gierend M, et al. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepatogastroenterology. 2004;51(59):1345‒1349.
   PubMedGoogle Scholar
• Gross V, Bar-Meir S, Lavy A, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23(2):303‒312.
   PubMed Web of Science ®Google Scholar
• Testa A, Castiglione F, Nardone OM, et al. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 2017;11:297‒303.
   PubMed Web of Science ®Google Scholar
• Boyle M, Ting A, Cury DB, et al. Adherence to rectal mesalamine in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(12):2873–2878.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. J Crohns Colitis. 2016;10(7):828‒836.
   Web of Science ®Google Scholar
• Bager P, Julsgaard M, Vestergaard T, et al. Adherence and quality of care in IBD. Scand J Gastroenterol. 2016;51(11):1326‒1331.
   Web of Science ®Google Scholar
• Abdalla M, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17(11):1549–1559.
   PubMed Web of Science ®Google Scholar